7,478 Shares in iShares U.S. Pharmaceuticals ETF $IHE Purchased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. bought a new position in shares of iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 7,478 shares of the company’s stock, valued at approximately $752,000.

Several other hedge funds and other institutional investors have also modified their holdings of IHE. Bank of America Corp DE grew its position in iShares U.S. Pharmaceuticals ETF by 2.8% in the first quarter. Bank of America Corp DE now owns 456,606 shares of the company’s stock valued at $39,579,000 after acquiring an additional 12,565 shares during the period. MinichMacGregor Wealth Management LLC acquired a new position in iShares U.S. Pharmaceuticals ETF during the third quarter worth $32,098,000. Insight Wealth Strategies LLC lifted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 3.3% during the second quarter. Insight Wealth Strategies LLC now owns 122,642 shares of the company’s stock valued at $12,055,000 after acquiring an additional 3,950 shares during the period. Cetera Investment Advisers lifted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 675.4% during the first quarter. Cetera Investment Advisers now owns 109,471 shares of the company’s stock valued at $9,489,000 after acquiring an additional 95,353 shares during the period. Finally, Congress Asset Management Co. bought a new position in shares of iShares U.S. Pharmaceuticals ETF during the third quarter valued at $56,000.

iShares U.S. Pharmaceuticals ETF Stock Performance

Shares of NYSEARCA:IHE opened at $106.72 on Wednesday. iShares U.S. Pharmaceuticals ETF has a 52 week low of $75.03 and a 52 week high of $109.43. The company’s fifty day moving average is $102.42 and its 200-day moving average is $94.95. The company has a market capitalization of $1.61 billion, a PE ratio of 17.75 and a beta of 0.47.

iShares U.S. Pharmaceuticals ETF Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.